Mylan to Initiate Clinical Studies for Generics of GSK’s Advair Diskus and Sanofi’s Lantus
Mylan Inc. is initiating Phase III clinical trials for generic versions of GlaxoSmithKline’s respiratory drug Advair Diskus (fluticasone and salmeterol) and an insulin analog to Sanofi’s Lantus (insulin glargine) for treating Type I and Type II diabetes.
In October 2014, Mylan will begin a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients. The study is expected to be completed in April 2015. In August 2014, Mylan initiated two Phase III clinical trials for its insulin analog program. These studies are expected to be completed in June 2016.
Source: Mylan